Human herpesvirus-6A (HHV-6A) is rarer than HHV-6B in many infant populations. However, they are similarly prevalent as germline, chromosomally integrated genomes (ciHHV-6A/B). This integrated form affects 0.1-1 % of the human population, where potentially virus gene expression could be in every cell, although virus relationships and health effects are not clear. In a Czech/ German patient cohort ciHHV-6A was more common and diverse than ciHHV-6B. Quantitative PCR, nucleotide sequencing and telomeric integration site amplification characterized ciHHV-6 in 44 German myocarditis/cardiomyopathy and Czech malignancy/inflammatory disease (MI) patients plus donors. Comparisons were made to sequences from global virus reference strains, and blood DNA from childhood-infections from Zambia (HHV-6A mainly) and Japan (HHV-6B). The MI cohort were 86 % (18/21) ciHHV-6A, the cardiac cohort 65 % (13/20) ciHHV-6B, suggesting different disease links. Reactivation was supported by findings of 1) recombination between ciHHV-6A and HHV-6B genes in 20 % (4/21) of the MI cohort; 2) expression in a patient subset, of early/late transcripts from the inflammatory mediator genes chemokine receptor U51 and chemokine U83, both identical to ciHHV-6A DNA sequences; and 3) superinfection shown by deep sequencing identifying minor virus-variants only in ciHHV-6A, which expressed transcripts, indicating virus infection reactivates latent ciHHV-6A. Half the MI cohort had more than two copies per cell, median 5.2, indicative of reactivation. Remarkably, the integrated genomes encoded the secreted-active form of virus chemokines, rare in virus from childhoodinfections. This shows integrated virus genomes can contribute new human genes with links to inflammatory pathology and supports ciHHV-6A reactivation as a source for emergent infection.
INTRODUCTION
Herpesvirus establishes latent infection through an episomal form with limited gene expression, in contrast to the lytic phase with full gene expression and rolling circle concatameric replication, which is also episomal within the host nucleus. Unique among human herpesviruses (HHV), HHV-6A and HHV-6B have been shown recently to integrate into the germline of human chromosomes in approximately 0.1 to 1 % of the human population (Hall et al., 2008; Leong et al., 2007; Potenza et al., 2009; TanakaTaya et al., 2004) as reviewed by Morissette & Flamand (2010) and Pellett et al. (2011) . This appears a specific event involving homologous recombination between telomeric repeat sequences at the ends of both the virus and human genomes, giving integration at the chromosome subtelomeric junction. The resulting 159 kb virus genome addition could potentially express over 100 viral genes in every cell of the body (Arbuckle et al., 2010; Arbuckle & Medveczky, 2011) . The effects on health are only beginning to be assessed, and the relationship between the integrated genomes and virus are not clear. However, understanding these relationships are key to understanding their effects.
Gene expression at the telomere has been previously thought to be genetically silent with transcription repression. Such 'silencing' would be a good strategy for virus latency in the somatic genome. There is some evidence for telomeric latency and reactivation from studies in cell lines (Arbuckle et al., 2010; Arbuckle & Medveczky, 2011) . However, in the germline-integrated HHV-6 genome, where there is also active telomere maintenance, gene expression may affect foetal development, as well as generation of the immune system and its regulation, particularly as the virus encodes potent immune modulators. Recent studies on the human telomere, and related model systems, suggest a dynamic system of repression and derepression cycles in the subtelomeric region related to chromatin structure, possible post-transcriptional regulation, increased recombination effects, and active transcription at the subtelomere to telomere regions by the TERRA transcript (Caslini, 2010; Loney et al., 2009; Tan et al., 2012) . Therefore, integration of the virus genome in the germline at this site could have a variety of outcomes: active gene expression (new human genes), virus reactivation (emergent infection) or genetically silent (no expression or virus reactivation). There could also be effects on chromosomal arrangements, but given the apparent specificity of the genome integration, this may only be in rare cases. This complexity is doubled, as HHV-6 comprises two species, A and B, and both these human viruses can accomplish this integration. Therefore, it is crucial to understand these genotypes and their distinctions in order to assess effects on human health.
Like many herpesviruses, both HHV-6A and HHV-6B establish latent infections during childhood, which persist for the lifetime, and may reactivate later to cause pathology. Infant infection is symptomatic, with fever and occasional severe complications including encephalitis. Reactivated infections show more severe inflammatory pathology under immunosuppressive or dysregulated conditions. Both HHV-6A and HHV-6B have been identified as commensals of the brain and linked to encephalitis, reflecting the close relationship (Virtanen et al., 2007; Ward et al., 2005) . However, there are distinctions in inflammatory complications between HHV-6A and HHV-6B, which may reflect different integration behaviour and associated coding potentials. Both viruses encode potent immunomodulators. These include chemokines plus their receptors, which could dysregulate the inflammatory response, and these have different specificities (Catusse et al., 2008 (Catusse et al., , 2009 Dewin et al., 2006; Fitzsimons et al., 2006; Lüttichau et al., 2003) . Studies in countries where HHV-6B is prevalent show that complications include childhood febrile status epilepticus, linked to hippocampus involvement and a risk factor for temporal lobe epilepsy development (Epstein et al., 2012) , as well as cognitive dysfunction or fatal encephalitis in haematopoietic stem cell transplantation patients (Zerr, 2006; Zerr et al., 2011) . By contrast, in these countries with childhood HHV-6B, HHV-6A appears to be an emergent infection and linked with distinct neuroinflammatory disease, either involving glial cells and demyelination as in multiple sclerosis, general encephalopathy or glial malignancy (glioma) (Akhyani et al., 2000; Alvarez-Lafuente et al., 2002; Ben-Fredj et al., 2013; Caselli et al., 2002; Cermelli et al., 2003; Chi et al., 2012; Crawford et al., 2009; Goodman et al., 2003; Kawabe et al., 2010; Virtanen et al., 2011; Yoshinari et al., 2007) . Recent studies also link HHV-6A and HHV-6B with other inflammatory diseases including cardiovascular diseases (myocarditis and idiopathic-cardiomyopathy) (Bigalke et al., 2007; Krueger et al., 2008; Kühl et al., 2005a, b) and those in the thyroid (Hashimoto's thyroiditis, mainly HHV-6A) (Caselli et al., 2012) .
Since HHV-6A and HHV-6B are inflammatory disease associated, in particular cardiac as well as neuroinflammatory, we sought to examine chromosomally integrated (ci) HHV-6A and ciHHV-6B genes, including inflammatory mediators, in two distinct European cohorts derived after extensive clinical screening at specialist centres investigating chromosomal integration, one a European centre for cardiovascular disease, in Germany, the other a central referral clinic for haematological and neurological disorders in the Czech Republic. The Czech cohort included 14 cases of ciHHV-6 previously identified in patients with malignancies (Hubacek et al., 2009a (Hubacek et al., , 2013 and typed with HHV-6 U65/66A or B specific real-time PCR giving 11 (79 %) with HHV-6A and 3 (21 %) with HHV-6B. This screening of 1151 patients gave a prevalence of 1.22 %. This is similar to that described for the UK and USA, 0.8 and 1.0 %, respectively (Morissette & Flamand, 2010; Pellett et al., 2011) , but those had only 9 (26 %) ciHHV-6A and 25 (74 %) ciHHV-6B from donors where chromosomal integration sites were mapped. In the only study where postnatal and congenital (from primarily germline chromosomal integration) infection were compared (USA) in 43 congenital infections, 32 % were ciHHV-6A compared with 2 % HHV-6A in 42 postnatal infections (Hall et al., 2008) . A larger study of postnatal virus infection in over 2000 infants showed 97 % HHV-6B and 3 % HHV-6A in the USA, with HHV-6A infant infections rarely reported in Europe and Japan, while in southern Africa (Zambia) HHV-6A was in over 90 % of children (Bates et al., 2009; Hall et al., 2006 Hall et al., , 2008 . This apparent conundrum in distinct prevalence of ciHHV-6A/ B compared with virus infections with HHV-6A/B could be due to differences in integration efficiency, distinct origins or different capacity for virus reactivation. This is investigated here with 44 ciHHV-6 identified (29 ciHHV-6A and 15 ciHHV-6B), the largest single study to date, with characterization of genotypes at multiple selected loci and analyses of phylogenetic relationships in comparison with genotypes from virus infection with HHV-6A and HHV-6B.
RESULTS
U83 chemokine gene structure is different in ciHHV-6A and ciHHV-6B, and encodes the active form The U83 chemokine gene was first analysed in the ciHHV-6A/B genomes. This gene is the only HHV-6A/B divergent gene that is specific for these viruses. It is not conserved in the closest relation, HHV-7, which has not been observed to integrate into the human germline genome, and thus also constitutes a gene acquisition which may be essential for ciHHV-6A/B (Dominguez et al., 1999; Gompels & Kasolo, 2006; . The U83 chemokine gene is distinct between HHV-6A and HHV-6B strains, encoding up to 13 % amino acid differences (French et al., 1999) . The HHV-6A (U83A) and HHV-6B (U83B) chemokines have distinct specificities which determine chemoattraction or diversion of different leukocyte subsets for infection or immune evasion, thus an early component of cellular tropism as well as mediator of innate immunity (Catusse et al., 2007 (Catusse et al., , 2009 Clark et al., 2013; Dewin et al., 2006; Lüttichau et al., 2003) . U83 also has a varied gene structure, with N-terminal length variation determining production of the encoded mature secreted chemokine, coupled with control by cell-directed splicing which truncates the chemokine gene early in replication to encode an antagonist (Dewin et al., 2006) . Splicing is inhibited by the virus late in replication when the full-length transcript and encoded agonist is produced (Dewin et al., 2006; French et al., 1999) . Therefore, this gene can also serve as a marker for early/late gene expression transition. Moreover, most HHV-6A/B strains have been analysed for this gene, therefore making it a good target to analyse or distinguish HHV-6A/B-compared with ciHHV-6A/B-encoded features.
The sequence databases are dominated by HHV-6B strains (Sjahril et al., 2009) , primarily from Japan where infant infections with this virus are common and HHV-6A is rare. We therefore first analysed further HHV-6A strains from infant infections and childhood human immunodeficiency virus (HIV)/AIDS mortalities we had previously identified in Zambia, where both HHV-6A and HHV-6B are prevalent in infant infections (Dewin et al., 2006; French et al., 1999) . In previous gene expression analyses by cDNA characterization, our studies had shown there was a T polymorphism in a rare cDNA from HHV-6 U83A, strain U1102, from an early in vitro passage, which gave a frame shift leading to alternative use of a primary initiating methionine encoding the signal sequence now in-frame with the rest of the U83 coding sequence, which would allow efficient secretion of the mature chemokine (termed here 'long' form U83) similar to U83B (Dewin et al., 2006) . The products of these 'long' forms of both the U83A and U83B genes have been extensively characterized as secreted, active chemokines with distinct specificities (Catusse et al., 2007 (Catusse et al., , 2009 Dewin et al., 2006; Lüttichau et al., 2003; Sjahril et al., 2009) . However, in studies of virus strains from both HHV-6A and HHV-6B, most have other T polymorphisms, which cause frame shifts that would reduce expression of this gene by being out of frame with the rest of the U83 coding sequence. This could cause termination of translation at the next stop codon, eliminating expression of U83. Alternatively, pending an appropriate transcript secondary to the first initiating codon or leaky scanning of the ribosome from an adequate but less than perfect initiating codon (23G, no +1G) to a favoured one (23G, +1G) (GAAATGT to GTTATGG) (Kozak, 1989 (Kozak, , 1995 , this could result in utilization of the second internal in-frame initiating methionine codon. Even under these conditions, this would encode a product that is not secreted, hence inactive, or only very inefficiently secreted, since the encoded signal sequence is poorly predicted to be utilized, termed here the 'short' form of U83A or U83B (Clark et al., 2013; Dewin et al., 2006; Sjahril et al., 2009 ) (see virus reference sequences in Figs 1, 2 and S1, available in the online Supplementary Material).
The gene structure of the U83 chemokine gene was further examined in the HHV-6A/B virus infections from Zambia, since to date this is the only region where natural HHV-6A infant infections are equally prevalent with HHV-6B infections (Bates et al., 2009; Clark et al., 2013; Kasolo et al., 1997) and, therefore, the structure of virus U83A in particular can be examined here. Fig. 1(a) shows that the HHV-6A U83A genes are all the 'short' form while the HHV-6B genes are also mainly the 'short' forms. This is similar to results for strains from infant infections with HHV-6B in Japan where there appeared a mix of 'long' and 'short' forms in infant infection (Sjahril et al., 2009) . When the U83 gene structure was examined in the ciHHV-6A/B genomes, surprisingly, these encoded primarily the fulllength, secreted mature 'long' form, with significantly increased prevalence (Figs 1b and 2, Table 1 ). These genes have the capacity to express the longer protein if an appropriate transcript is expressed.
Chromosome 17p was a favoured integration site identified by amplification of the DR-telomere junction in 16/44 (36 %) genotypes (Fig. 2) . Interestingly, almost all U83A long form genes were from 17p-integrated ciHHV-6 (12/ 14, 86 %), whereas this form has rarely been identified in virus infection. In summary, HHV-6A U83A is the 'short' form, and HHV-6B U83B is a mixture of 'long' and 'short' forms. In contrast, ciHHV-6 genomes have mainly the long active U83 form.
Genotype analysis at multiple loci shows greater ciHHV-6A divergence All ciHHV-6A/B genotypes were analysed at four loci, using selected conserved (U38) and divergent (U46 and U83) loci, plus a further virus-encoded inflammatory mediator gene, U51. This conserved, early expressed chemokine receptor, is required for efficient replication, and has sensitive signalling mechanisms, both inducible and constitutive, with immune regulatory function (Catusse et al., 2008; Fitzsimons et al., 2006; Milne et al., 2000; Zhen et al., 2005) . This was combined with analyses of the divergent U46, encoding glycoprotein gN, a component in complex with gM, also essential for infection (Kawabata et al., 2012) and previously used to genotype the predominant HHV-6A virus infecting children in Zambia (Bates et al., 2009 ). This locus is also located at one of the main sites for virus recombination leading to the distinct mammalian herpesvirus lineages, and thus a potential recombination marker Mattick et al., 2004) . Finally, a gene fragment encoding the conserved U38 DNA polymerase catalytic domain was also analysed as a central conserved gene encoding the core DNA polymerase essential for virus replication.
The U38, U46, U51 and U83 PCR amplicon sequences were compared to those from all available virus strains sequenced, including an additional HHV-6A reference strain, AJ (determined here using these selected amplicons, in Methods), derived from an HIV/AIDS patient in the Gambia and cultivated in the UK (Tedder et al., 1987) as well as Zambian virus strains previously characterized for U46 (Bates et al., 2009) . Overall characterization at the four loci defined the German cardiac set as 65 % (13/20) ciHHV-6 B and 35 % (7/20) ciHHV-6A. By contrast, in the Czech malignancy/inflammatory disease cohort only 14 % (3/21) were ciHHV-6B, the rest 86 % (18/21) were
HHV-6 Zambian infants HHV-6 Zambian child HIV/AIDS 8 IDs Integrated herpesvirus genomes, reactivation and inflammation ciHHV-6A, although four of the ciHHV-6A genotypes showed evidence of recombination or superinfection with ciHHV-6B (see below). The Czech inflammatory disease subset was entirely ciHHV-6A (9/9).
Phylogenetic analyses showed that the ciHHV-6A genotypes are more divergent than the ciHHV-6B genotypes at all loci ( Fig. 3a-d) . Analyses of the most divergent locus, U83, also the locus with the most virus sequences available and alternative signal sequence, long (L) or short (S). By keeping the first initiating codon in-frame with the rest of the U83 coding sequence, the 59 T polymorphism in germline ciHHV-6A and ciHHV-6B gives the potential to switch on the encoded signal sequence for secretion of the mature U83 chemokine resulting in mainly the 'long' secreted form. This encoded 'long' secreted form was only found in ciHHV-6A. In ciHHV-6B, there was mainly the 'long' form, and also in two patients (*) there was an even longer extended form (+L) using an upstream encoded signal sequence, previously noted in variant populations of HHV-6B strain HST (Sjahril et al., 2009 ). Other details are as for Fig. 1 and as shown in Tables 2 and 3 . Shaded sample numbers indicate the telomeric integration site identified at chromosome 17p (see text). Ai-Aiv and Bi-Bv refer to the T polymorphism patterns in Fig. 1 .
globally for comparison (82 from NCBI, 112 total), showed that while ciHHV-6B U83B segregated with HHV-6B U83B strains, ciHHV-6A U83A genotypes were more divergent and there was a distinct ciHHV-6A clade encoding U83A (Fig. 3a) .
Where virus sequences were available from HHV-6A infant infections in Zambia, these were also distinct from ciHHV-6 (U46, Fig. 3c ). Analyses of the ciHHV-6B strains showed most were in a single clade. Initially, they grouped together with different circulating HHV-6B strains at the different loci analysed (for U38 mainly with Z29, for U46 mainly both Z29 and HST, for U51 with HST, but for U83 with other B strains).
When the groupings from Fig. 3 (a-d) were analysed together as summarized in Tables 2 and 3 , these were distinct genotypes and most clearly shown for ciHHV-6A. These were distinct from sequences available for global circulating virus strains from Asia (Japan), Africa (Uganda, Gambia, DR Congo and Zambia) and USA as well as Europe, including both UK and local virus strains from Germany, the same country as these ciHHV-6A/B patients (Figs 3a, c and Fig. S2 ). Whilst only integrated sequences were available from the Czech Republic, it is adjacent to Germany, has mixed populations, and the integrated sequences are related to each other, but distinct from the German virus sequences. The number of virus sequences available is a limitation and more international sequences will be useful. Analyses of encoded sequences of inflammatory modulator genes identified coding substitutions characteristic for ciHHV-6A in U83 (Table 4) . Overall, the genotypes of ciHHV-6A or ciHHV-6B were distinct, showing 1-3 % variation from virus nucleotide sequences, similar to that observed within respective HHV-6A or HHV-6B strains (Bates et al., 2009; Gompels & Kasolo, 2006) .
Copy number variation and recombination in ciHHV-6A genomes
The scatter of the copy numbers per cell were higher in the MI cohort than the cardiac cohort SD 5.7 of mean 4.0 (95 % CI of the SD 4.3-8.3) vs SD 0.3 of mean 0.8 (95 % CI of the SD 0.2-0.4), respectively, P50.018 by Welch's t-test (unequal variance). The coefficient of variation (SD/mean) also showed the distinct scatter of the two groups with 143 % for the MI set and only 4 % in the cardiac set. There are limitations to these data though, in that the screenings were conducted over 10 years, and with different genes for the calibration curves. In the absence of an international standard for HHV-6A or HHV-6B, this cannot be standardized at present to compare exact values. However, the MI 1-26.6 copies per cell range is above the 0.5-2.0 copies per cell assay variance (Methods). In median analyses, half of the MI set had copy numbers per cell greater than 2, median 5.2 with 2.5 median absolute deviation. None of the German cardiac set had copy numbers per cell greater than 2, they only had single copies. In the three donors available for analysis (two Czech, one transplant donor from Germany), these genomes were all ciHHV-6A, but below 2 copies per cell, and two of the three donor genomes encoded the 'short' form of the U83 chemokine, unlike the predominant 'long' form in the patient ciHHV-6A genomes.
In addition to variable copy numbers, some ciHHV-6A genomes also had evidence for recombination with HHV-6B. This was highlighted in 4/21 patients in the Czech MI cohort as in the multi-locus analyses. These included recombination events between (intergenic) ciHHV-6A and HHV-6B genes (30554, 12716, 22727) , and within (intragenic) genes (17172 and 22727) (Table 3) . Interestingly, the DNA polymerase locus appeared 'switched' to HHV-6B in 2/4 Czech inflammatory disease patients where other loci were ciHHV-6A (12716 and 30554). 12716 had a copy number per cell greater than 2 (4.6), so could be a superinfection or reactivation. Two of these patients showed evidence for intragenic recombination between the ciHHV-6A genome and HHV-6B virus in the U46 (17172) and U83 (22727) genes since both synonymous (non-coding) and non-synonymous (coding) SNPs were co-selected (Fig. 4a, b) . Three of the recombinants were in the inflammatory disease group (30 %; 3/10).
These analyses show that ciHHV-6A and -6B are profoundly different integrated genomes demonstrated by substantial differences in: 1) integrated versus non-integrated 'long' U83 genes, with the 'long' U83A being primarily associated with ciHHV-6A and rarely found in HHV-6A in contrast to ciHHV-6B where 'long' U83 is almost exclusively found and a mixture of forms during HHV-6B infection; 2) genome copy number per cell, with ciHHV-6A showing higher variance in a subset of patients; 3) recombination, with evidence for ciHHV-6A recombinants with HHV-6B. *Infection (HHV-6) and integration (ciHHV-6 with pathology) strains from this study (Figs 1 and 2 ). HHV-6B infection strains from Japan infant exanthem subitum (ES) and bone marrow transplantation patients (Sjahril et al., 2009) . DCategorical data analyses of prevalence of secreted 'long' forms of U83 chemokine encoded by strains from infection compared to integration (ciHHV-6) via Fisher's exact test with a two tailed P value, using the method of summing small P values.
Integrated herpesvirus genomes, reactivation and inflammation
Deep sequencing shows minor variants in ciHHV-6A genomes with gene expression
To explore possible reactivation, cDNAs were analysed for gene expression with the same primers as for the above nucleotide analyses by using reverse transcription (RT)-PCR. Of seven German cardiac patients who were followed at different time points, four showed evidence for gene expression at certain bleeds, but not at others. These were two with ciHHV-6B genomes (4152 and 5312) and two with ciHHV-6A genomes (4305/2284 and 4358/5714). These were confirmed at two loci (U83 and U51) and showed identical sequence as the integrated DNA genotypes, including separate bleeds (U83 , Fig. 5) ; other bleeds or patient cDNAs examined were negative (not shown), while cell GAPDH control was detected in all cDNA samples. There was not sufficient sample for additional transcript characterization.
In order to further understand the relationship between gene expression and virus reactivation, deep sequencing was conducted. This was based on analysing the four amplicons in two ciHHV-6A genomes where there was sufficient template available (1624/5055 and 4305/2284, from the German myocarditis set), the integration site was defined and the same (17p), and which were analysed for gene expression, one expressing (4305) and one silent (5055). These were compared with infected cell DNA from a distinct virus HHV-6A genome (AJ) in comparison with the reference virus genome U1102. All SNPs identified were confirmed by Sanger sequencing. U38 and U83 had sufficient SNPs relative to the reference virus HHV-6A U1102 for further minor variant comparisons, using a cutoff of 0.2 % (see Methods). The results in Table 4 show minor variants were identified in samples with virus gene expression, in the virus-infected cells (AJ) and in the cDNApositive ciHHV-6A 4305, but not in the cDNA-negative ciHHV-6A 5055. Interestingly these minor virus-variants were HHV-6A (similar but distinct to reference U1102). Furthermore, the minor variant SNPs identify a rare 'long' form of U83A in virus AJ (0.4 % ATG-long). Even though minor virus-variants were up to 40 % in ciHHV-6A 4305, the transcript sequences were identical to ciHHV-6A DNA. Further, the U83A cDNA was the unspliced late transcript, only expressed after DNA replication (French et al., 1999) . These results support the hypothesis that virus-superinfection reactivates the latent ciHHV-6A genome.
DISCUSSION
The 44 integrated ciHHV-6A/B genotypes showed distinctions from those associated with acute HHV-6A/B virus infection. Chromosomal integration at 17p was prevalent here, 31 ciHHV-6A (42 %) and 13 ciHHV-6B (23 %). 17p, as the shortest chromosome telomere may favour virus genome integration (Britt-Compton et al., 2006) . There was evidence for both ciHHV-6A (4305 and 4358) and ciHHV-6B (5312 and 5086) gene expression (U83 and U51) in a subset of the German cardiac cohort analysed, showing reactivation. Further mapping of transcripts will be of interest. The ciHHV-6A genotypes were more divergent than the ciHHV-6B genotypes, distinct from virus, and some showed evidence for recombination with HHV-6B. Global comparisons were made and though the largest study to date, it is limited by virus sequences available and more would elucidate relationships.
The increased, variable copy numbers in part of the MI ciHHV-6A cohort also support virus reactivation, where integrated ciHHV-6A genomes could be reactivated by superinfection with HHV-6B, as demonstrated by recombination. The deep sequencing results showed gene expression in ciHHV-6A patients who had superinfections with HHV-6A. Overall these data point to a model whereby ciHHV-6A genomes are reactivated by superinfection with HHV-6A/B. Potential virus reactivation or gene expression by virus superinfection also explains identification of cDNA from multiple genotypes observed in a ciHHV-6A case report as well as a mechanism for transplacental infection of infants by mothers with ciHHV-6A or recently demonstrated gene expression with virus reactivation and hemaphagocytic pathology from an X-SCID infant with ciHHV-6A (Endo et al., 2014; Gravel et al., 2013; Pantry et al., 2013) . Microbial superinfection has also recently been shown to induce reactivation of replication of the ciHHV-6 genome by T-loop ciGermany-Cardio-U38-3312 ciGermany-Cardio-U38-4305 ciGermany-Cardio-U38-4358 ciGermany-Cardio-U38-2476 ciGermany-Cardio-U38-3001 ciGermany-Cardio-U38-1624 ciGermany-Cardio-U38-2305 ciGermany-Cardio-U38-3040 ciGermany-Cardio-U38-3653 ciGermany-Cardio-U38-5057 ciGermany-Cardio-U38-2250 ciGermany-Cardio-U38-3003 ciGermany-Cardio-U38-4961 ciGermany-Cardio-U38-5086 ciGermany-Cardio-U38-5312 ciGermany-Cardio-U38-5178 ciGermany-Cardio-U38-5459
Japan-ES-U38-HST ciCzech-Donor-U38-39368 ciCzech-ALL-U38-18744 ciCzech-Donor-U38-36637 ciCzech-HL-U38-36848 ciCzech-Cardio-U38-15929 ciCzech-SAA-U38-17172 ciCzech-Neuro-U38-21846 ciCzech-HL-U38-25533 ciCzech-muscleconvulsion-U38-40672 ciCzech-SAA-U38- Zambia-infant-U46-39M18
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UK-HIVAIDS-U46-AJ O Uganda-HIVAIDS-U46-U1102
and a purported captured integrase gene from parvovirus, which has been shown as a potent replication inhibitor of HHV-6A/B (Caselli et al., 2006; Katsafanas et al., 1996; Rotola et al., 1998; Turner et al., 2002) .
Therefore, individual ciHHV-6A/B genomes may act differently. There is evidence here for virus reactivation from some ciHHV-6A genomes. However, other integrated genomes may be restricted to only gene expression or genetically silent. This may explain initial varying results with small patient groups. Thus in liver transplantation patients with ciHHV-6B genomes, there was increased prevalence of bacterial infection and graft rejection (Lee et al., 2011) suggesting effects of ciHHV-6B gene expression. While in malignancy patients, ciHHV-6A/B appeared to have similar prevalence to the general population, suggesting they were genetically silent in this context (Hubacek et al., 2013) . However, case reports link ciHHV-6A with neuroinflammatory disease and further show response to antiviral treatment, suggesting effects of virus reactivation or superinfection, though effects on inflammation require further investigation (Arbuckle et al., 2010; Montoya et al., 2012) .
The Czech inflammatory patient subset were all ciHHV-6A, and a subset of this group had evidence of increased copy number and also of recombination with HHV-6B, ciGermany-Cardio-U51-2229 ciGermany-Cardio-U51-2250 ciGermany-Cardio-U51-2305 ciGermany-Cardio-U51-3003 ciGermany-Cardio-U51-3040 ciGermany-Cardio-U51-3653 ciGermany-Cardio-U51-4152 ciGermany-Cardio-U51-4961 ciGermany-Cardio-U51-5057 ciGermany-Cardio-U51-5086 ciGermany-Cardio-U51-5178 ciGermany-Cardio-U51-5312 ciGermany-Cardio-U51-5459
Integrated herpesvirus genomes, reactivation and inflammation both indicative of virus reactivation. It is possible that the use of immunosuppressants, histone deacetylase (HDAC), inhibitors which affect chromatin condensation (i.e. trichostatin A) or anti-convulsants (such as carbamazepine), may favour virus reactivation as reviewed by Pellett et al. (2011) ; however, in this cohort this was not a major treatment option. Immune activation could be a factor. Inflammatory-mediating virus genes U83A and U51A have specific coding changes in the ciHHV-6A genotypes. Furthermore, the 'long' active form of U83A chemokine is the major form in ciHHV-6A, rarely observed in virus infections (Dewin et al., 2006) . By contrast, in both HHV-6A and HHV-6B, U83A/B 'long' form prevalence is reduced by the effects of homopolymeric frame shifts (Figs 1 and 2 , Tables 1 and 4, Fig. S1 ) (Dewin et al., 2006; Sjahril et al., 2009 ). These are a characteristic feature of some herpesvirus genes, which may affect gene control as recently reviewed by Szpara et al. (2014) and Wilkie et al. (2013) . The 'long' active form of U83A has a unique broad specificity for receptors CCR1, CCR4, CCR5, CCR6 and CCR8 present on plasmacytoid and myeloid dendritic and monocyte/macrophage antigen presenting cells, as well as both TH1 and TH2 skin homing lymphocytes and NK cells; it is also amongst the highest affinity ligands for CCR5 and inhibits HIV-1 binding at this coreceptor (Catusse et al., 2007 (Catusse et al., , 2009 Dewin et al., 2006) . U83A can both block and divert human chemokine action while occupying the human chemokine receptors. While the U51A chemokine receptor has a complementary function, by affecting the key remaining beta-chemokine receptors. This gives U51 a unique specificity distinct from cellular receptors, having overlapping reactivities similar to CCR2, CCR3, XCR1 and CCR7, and combining both constitutive as well as inducible immunoregulatory signalling activities (Catusse et al., 2008; Fitzsimons et al., 2006; Milne et al., 2000) . Unlike human chemokines, the U83A chemokine does not interact with DARC or D6 regulatory chemokine receptors. Thus, combined activities of U51A together with U83A can dysregulate the entire human beta-chemokine system and distort trafficking to lymph nodes (Catusse et al., 2009 ). This could affect regulation of human chemokines recently defined in cognitive development and is consistent with a role in neuroinflammatory pathologies (Villeda et al., 2011) . Chemokine receptors recognized by U83A or U83B are also present on sperm or oocyte cells and thus virus chemokine expression may be central for virus-mediated chemoattraction of the germline cell for infection, then subsequent integration.
The German cardiovascular disease cohort associated mainly with ciHHV-6B. Although some recurrent cardiomyopathy cases could be from superinfection/reactivation as identified in the few ciHHV-6A examples, this result is consistent with expression of the active 'long' form of U83B chemokine. This mimics human CCL2 (MCP-1, monocyte chemotactic protein-1), which is associated with cardiovascular disease, via mediating traffic and activation of proinflammatory *Disease and patient code number: ALL, acute lymphoblastic leukaemia; HL, Hodgkin lymphoma; LiverTX, neurological infection in liver transplantation patient; neurol, neurinflammatory; neurolLyme, neuroinflammatory, Lyme disease testing; dob, date of birth of healthy donor, donorCML, donor for chronic myeloid leukaemia; Immdef(HIV-), immunodeficiency patient, HIVnegative; SAA, severe aplastic anaemia; MDS, myelodysplastic syndromes (note this premalignant condition could also be considered under the malignancy set); Cardio, pericarditis; ESarc, Ewing sarcoma; AML, acute myeloid leukemia; MS, multiple sclerosis; samples in bold type indicate integration site at telomere of chromosome 17p by amplification of the integration site. DViral copies/human copies/25viral copies per diploid cell. DNA extracted from blood, except sample 21846 from cerebrospinal fluid (CSF). monocytic and dendritic cells expressing the CCL2 receptor CCR2 (Bates et al., 2009; Clark et al., 2013; Niu & Kolattukudy, 2009 ). These effects on innate immunity may underlie other intracellular cardiotropic pathogens such as parvovirus B19 (Tzoulaki et al., 2013) . Of note, parvovirus B19 and HHV-6 are the two most common virus DNAs detected in endomyocardial biopsies from patients with left ventricular dysfunction and lack of virus genome clearance, as for ciHHV-6, associated with progressive impairment (Kühl et al., 2005a, b) .
The ciHHV-6A diversity plus copy number variation, evidence for ciHHV-6A recombination with HHV-6B, and frequency of the 'long' active form of the U83A chemokine gene in ciHHV-6A provide evidence for divergence between the HHV-6A and HHV-6B lineages and their integration events. The potent properties of the chemokine and chemokine receptors encoded by the virus, together with the active alleles present in the ciHHV-6 genomes, and evidence for gene expression in a subset of patients, indicate these are novel human genes of original virus origin, which (French et al., 1999) .
may underlie diverse inflammatory conditions. The demonstration of superinfection by deep sequencing of ciHHV-6A genomes with gene expression shows a mechanism for virus reactivation which, combined with the encoded chemokine leukocyte chemoattractant properties, could allow dissemination and emergent infections.
METHODS
Ethics statement. Anonymized samples were part of previous cohorts with ethical approval and patients' written consent for endomyocardial (EMB) biopsy or blood for analysis at Charite campus, Germany and Charles University, Czech Republic (Hubacek et al., 2013; Kühl et al., 2005a, b) or University Teaching Hospital, Lusaka, Zambia and the London School of Hygiene and Tropical Medicine (Bates et al., 2009 ).
Patients and ciHHV-6 DNA screening. DNA was screened from EMB biopsies and confirmed in blood samples of patients with clinically suspected acquired cardiomyopathies or persisting heart failure symptoms who were HHV-6+ by PCR; 548/3610 patients (14.4 %) were cardiac HHV-6 positive. Of these, 21/548 (5 %) or 21/ Uganda-HIVAIDS-U46-U1102
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DRCongoHIVAIDS-HHV6B-Z29 locus. Copies were determined relative to human genome copies calculated from the molecular mass of the extracted blood DNA sample. RNA was extracted and cDNA prepared in a subset of EMB biopsies and blood using Trizol reagent and reverse transcriptase as described previously for this cohort (Kühl et al., 2005b) . In the Czech set from malignancies, with lymphoproliferations, or inflammatory disease patients, copy number of both viruses, across the U65/66 locus, and human albumin genes were determined by real-time quantitative PCR using a HHV-6A/B-specific Taqman assay, and the relative copy number subsequently determined (error ±1 C t ; 0.5-2
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HHV-6A (Boutolleau et al., 2006) . In the Czech set, germline integration was also confirmed by Taqman detection of virus genomes in DNA extracted from nail clippings, as described by Hubacek et al. (2013) , with prevalence approximately 1 % in different cohorts. Fig. 5 . Identity between sequences from cDNA and genomic DNA from ciHHV-6A and ciHHV-6B. Nucleotide sequence was derived from cDNA and genomic DNA from amplicons derived from the ciHHV-6A or ciHHV-6B patients indicated. Some of the genomic DNA was from different bleeds from the same patient as indicated by 'ii'. Results are shown for the U83 gene. Asterisks show residues distinguishing the ciHHV-6A or ciHHV-6B genes from representative reference virus strains. See 112 in Fig. 3 and S2.
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On: Fri, 07 Dec 2018 00:25:29 U83RP1 59-TGCCATATCACACATCGAG-39; and U51 with: IU51SF1 59-GTCAATACGGATGGGGTTTTG-39) and IU51SR2 59-CAGCGC-CGAAGATCTATTCT-39 (all nucleotide primers synthesized by SigmaAldrich). To amplify the U83 locus (primers BHU83F, U83FP1, U83RP1), a semi-nested PCR procedure was used for some samples using primers BHU83F1 and U83RP1, then a second step using primers U83FP1 and U83RP1; some additional primers were used to confirm sequence differences as described by Bates et al. (2009) and Clark et al. (2013) . To amplify the chromosome 17p telomere integration site, primers were 17p (59-AACATCGAATCCACGGATTGCTTTGTGTAC-39) and HHV-6 DRR (59-CATAGATCGGGACTGCTTGAAAGCGC-39) in a PCR to generate a 1.5 kb amplicon confirmed by sequencing, as described by Arbuckle et al. (2010) and Britt-Compton et al. (2006) .
PCR amplifications used GoTaq green mastermix (Promega), with nuclease-free H 2 O (Sigma). Negative controls (water as template) were included every 10 reactions. All the reaction preparations, template then addition and amplicon analyses were performed in three separate facilities to control clinical contamination. Amplifications were performed on a DNA Engine DYAD Peltier Thermal cycler (Bio-Rad) with the following thermocycling conditions: hot start at 95 uC for 2 min, then 50 cycles of 95 uC for 20 s denaturation, followed by 55 uC for 30 s annealing, then extension at 72 uC for 2 min, and final elongation at 72 uC for 5 min. The PCR products were separated by 1 % agarose gel electrophoresis, then gel purified using a PureLink Quick Gel Extraction and PCR Purification Combo kit (Invitrogen) and resuspended in water.
Sanger nucleotide sequencing and bioinformatics analyses.
DNA sequencing reactions used the amplification primers with the BigDye Terminator v3.1 Cycle Sequencing kit protocol (Applied Biosystems) in MicroAmp Optical 96-well reaction plates with barcode (Applied Biosystems), with thermocycling parameters of 94 uC for 4 min then 25 cycles of 96 uC for 20 s, 50 uC for 10 s and 60 uC for 2 min. Sequences were resolved using an ABI Prism 3730 DNA analyser (Applied Biosystems), then visualized and edited using Chromas 1.61 software (Technelysium). Sequences were resolved from both forward and reverse primers and also confirmed in multiple independent amplifications. Sequence comparisons used Basic Local Alignment Search Tool (NCBI-BLASTN) and multiple alignments of nucleotide and encoded amino acid sequences were performed with CLUSTAL W. Phylogenetic trees for nucleotide and encoded amino acid sequences were built using the maximumlikelihood method with all positions containing gaps and missing data eliminated and the tree reconstructed with the highest log-likelihood produced using MEGA5 (Tamura et al., 2011) . The nucleotide sequence trees were reconstructed using the Tamura-Nei model, uniform rates and close neighbour interchange, allowing for invariant sites, and checked with 1050 bootstrap replicates.
Deep sequencing and minor variant SNP analyses. Ampliconbased deep sequencing protocols were as described by Depledge et al. (2011) using ciHHV-6 genomes and reference HHV-6A strains U1102 and AJ. The U38, U46, U51 and U83 gene regions were targeted in PCR amplicons using the following primers: 3439F (59-TGCATTCTCTCACAGCATG-39), 3439R (59-TGTTTCCTTATG-\CCACCAATC-39); 7984F (59-AGATGTATGCTGAAGAACGTG-39), 7984R (59-GGATCGTCAACCGTTAGTG-39); 4549F (59-GAGTGCT-CGGATAAGTTCATT-39), 4549R (59-ACGATACAATCCGGAATGC-39); 4953F (59-TGGAACTCGGAATTGTTTCT-39), 4953R (59-GTTT-GAGACTGTATCTGCGCA-39). Thermocycling used hot start at 95 uC for 2 min, 35 cycles of 95 uC for 20 s, 59 uC for 30 s, 70 uC for 6 min, and a final elongation step of 72 uC for 10 min. PCR products were size-selected on 0.7 % agarose gels, then purified using the Wizard SV gel and PCR clean-up kit (Promega). Pooled equimolar amplicons were sheared using an E210 focused-ultrasonicator (Covaris) to a mean size of 200 bp, then purified using Agencourt AMPure XP beads (Beckman Coulter), followed by end repair, dA-tailing, adaptor ligation and PCR enrichment using the NEBNext DNA library prep master mix set for Illumina with multiplex oligos (New England Biolabs). Post reaction clean-up used Agencourt AMPure XP beads. DNA quality and quantification of the prepared libraries was assessed by using an Agilent high sensitivity DNA kit (Agilent) and Qubit 2.0 fluorometer (Invitrogen). Indexed DNA libraries were denatured, diluted and then loaded onto a MiSeq v2 reagent cartridge following the MiSeq guide (Illumina) for 26150 bp paired-end sequencing.
Assessment of raw-sequence data quality was performed with FastQC (Babraham Bioinformatics). Fastq file reads were subjected to adaptor removal, quality trimming using a phred score of 33 and minimum length of 100 bp with trimmomatic version 0.32 (Bolger et al., 2014) . Trimmed reads were mapped to the HHV-6A U1102 reference genome (accession X83413.1, RefSeq NC_001664.2) using the BWA-MEM alignment algorithm and SAMtools . Variant calling used a SAMtools mPILEUP, BCFtools, vcfutils varFilter pipeline (Danecek et al., 2011) and GATK UnifiedGenotyper . Reads with mapping quality scores .25 were used to calculate likelihoods at sites before bcftools was utilized to call variants. SNPs were filtered using vcfutils varFilter with minimum and maximum read-depths adjusted to 10 and twice the mean read depth, respectively. A cut-off for SNP sensitivity was further applied using an internal database control. This was a CG inversion misread corrected in 2006 (Dewin et al., 2006) but still on the reference genome (Table 4) . Here 0/6148 depth was detected, giving a sensitivity of 0.02 %; therefore a cut-off 1 log above this was applied to verify SNPs, a sensitivity of 0.2 %, and SNPs confirmed by Sangersequencing (Table 4) .
Reference sequences. HHV-6A sequence accession numbers for the complete genome of strain U1102 and the polymerase fragment of strain AJ, from Ugandan and Gambian HIV/AIDS patients (Downing et al., 1987; Tedder et al., 1987) , are X83413.1 and M87045, respectively. HHV-6B accession numbers for the complete genome sequences of strains Z29 and HST, from HIV/ AIDS patients from the Democratic Republic Congo and Japanese exanthem subitum (ES) patients, are AF157706.1 and AB021506.1, respectively.
